Allogene Therapeutics (ALLO) Earnings Date & Reports

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases... Show more

Industry: #Biotechnology

Get AI intraday signals

A.I. Advisor

published Earnings

ALLO is expected to report earnings to fall 1.00% to -17 cents per share on August 05

Allogene Therapeutics ALLO Stock Earnings Reports

Q2'26

Est.

$-0.18

Q1'26

Beat

by $0.01

Q4'25

Beat

by $0.06

Q3'25

Beat

by $0.03

Q2'25

Beat

by $0.04

The last earnings report on May 13 showed earnings per share of -18 cents, beating the estimate of -18 cents. With 9.05M shares outstanding, the current market capitalization sits at 707.57M.

View a ticker or compare two or three

Compare

ALLO

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days

View AI-Driven Trading for ALLO